IFWM
RXRX icon

Institute for Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Institute for Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-580,997
Closed -$3.93M – 545
2024
Q4 		$3.93M Buy
+580,997
New +$3.91M 0.49% 35
2024
Q3 		– Sell
-580,997
Closed -$4.36M – 554
2024
Q2 		$4.36M Sell
580,997
-152
-0% -$1.33K 0.58% 33
2024
Q1 		$5.79M Buy
+581,149
New +$6.47M 0.75% 16

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Institute for Wealth Management's RXRX Position: Q1 2025 in Review

Institute for Wealth Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2025, closing a stake of 580,997 shares — an estimated $3.93M sold.

Institute for Wealth Management first reported a position in RXRX in Q1 2024 and held it in 3 quarters. The position peaked at $5.79M in Q1 2024. 336 funds tracked by Wall St. Rank hold RXRX as of Q1 2025.

  • Institute for Wealth Management reported no remaining Recursion Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Institute for Wealth Management sold 580,997 Recursion Pharmaceuticals shares in Q1 2025, an estimated $3.93M.
  • Institute for Wealth Management first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Institute for Wealth Management's Recursion Pharmaceuticals position peaked at $5.79M in Q1 2024.
  • 336 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2025.

Based on Institute for Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.